Eisai sales and marketing update

Eisai said the Cancer Drugs Fund (CDF) panel upheld an appeal from the company to reconsider a January decision from NHS England to remove breast cancer drug Halaven eribulin mesylate from the CDF. Eisai said the decision came one day before Halaven was slated to lose CDF coverage. The drug will now remain on the CDF pending reconsideration this month (see BioCentury, Jan. 12). ...